Inion's BioRestore glass fibre bone graft substitute:
This article was originally published in Clinica
Executive Summary
Finnish firm Inion has received 510(k) clearance from the US FDA for its BioRestore bone graft substitute. The product, made from bioactive glass fibres, is designed to fill bony voids resulting from surgery or traumatic injury. The implant accelerates the formation of new bone, while gradually degrading over six months to allow the bone to fill the void. BioRestore is now approved for use in dental and cranio-maxillofacial applications, but is also being reviewed by the FDA for use in orthopaedic trauma indications. The US market for synthetic bone graft substitutes is estimated at around $158m, claimed the Tampere firm. Inion hopes to gain CE-marking for BioRestore during the second half of 2007 and plans to launch the product in Europe soon after.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.